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Abstract
This study examined study product adherence and its determinants in the Botswana oral pre-
exposure prophylaxis efficacy trial. Among the 1,219 participants, the mean adherence by pill 
count and 3-day self-report was 94 % for each. In multivariable models, pill count adherence was 
significantly associated with adverse events (nausea, dizziness, vomiting) (RR 0.98 95 % CI 0.98–
1.00; p = 0.03) and side effect concerns (RR 0.98 95 % CI 0.96–0.99; p = 0.01). Self-reported 
adherence was significantly associated with having an HIV-positive partner (RR 1.02 95 % CI 
1.00–1.04; p = 0.02) and Francistown residence (RR 0.98 95 % CI 0.96, 0.99; p = 0.0001). 
Detectable drug concentrations showed modest associations with self-report and pill count 
adherence, and drug levels were higher among those self-reporting 100 % adherence than those 
reporting <100 %. Most common adherence barriers involved refill delays and other logistic 
challenges; cellphone alarm reminder use was the most common facilitator.
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Introduction
A series of landmark clinical trials have demonstrated that daily oral pre-exposure 
prophylaxis (PrEP) can be highly efficacious in preventing HIV acquisition. The Botswana 
trial, known as the TDF2 trial, showed that a regimen containing tenofovir disoproxil 
fumarate and emtricitabine (TDF/FTC, known by the brand name Truvada®) was 62.2 % 
efficacious in preventing HIV infection among at-risk young men and women [1]. Other 
prevention trials have similarly established proof of concept for daily oral PrEP among 
samples of adult heterosexual African men and women in serodiscordant partnerships 
(partners PrEP trial) [2], among men who have sex with men (MSM) and transgender 
women who have sex with men (iPrEx trial) [3, 4].
Trials of daily oral PrEP regimens indicate that the efficacy of PrEP for HIV prevention may 
be importantly influenced by adherence. Among a subset of Partners PrEP participants who 
received active drug, plasma drug concentration assays showed detectable drug in 31 % of 
participants who seroconverted, compared to 82 % of a matched sample of participants who 
remained uninfected [2]. A similar pattern was observed in the TDF2 trial, where detectable 
TDF/FTC drug concentrations were found in 50 % (2 of 4) of participants who became HIV 
infected, compared to 80 % (55 of 69) for tenofovir (TFV) and 81 % (56 of 69) for 
emtricitabine (FTC) of a matched sample that did not seroconvert [1]. Data from PrEP trials 
conducted to date collectively show a dose–response pattern, in which greater product 
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adherence corresponds to higher PrEP efficacy [5, 6]. The FEM-PrEP trial among at-risk 
adult women in Kenya, South Africa, and Tanzania showed low adherence and was unable 
to demonstrate a protective effect [7]. Likewise, the vaginal and oral interventions to control 
the epidemic (VOICE) study among adult women in South Africa, Zimbabwe and Uganda 
was unable to demonstrate efficacy due to adherence challenges [8]. The data and outcomes 
from these PrEP trials suggest that study product adherence may represent the “Achilles 
heel” for PrEP as an HIV prevention strategy [5, 9].
The assessment of adherence has proven challenging in daily oral PrEP trials. PrEP trials 
have used combinations of self-reported adherence, pill counts, dispensation (or time-to-
refill) measure, and drug concentrations in blood plasma [10]. There have been reports that 
study product adherence showed modest or transient declines over time in some trials [3, 
13]. Results to date generally indicate that self-reported measures over-estimate adherence 
relative to other measures [10, 11]. Data from the VOICE trial was particularly concerning 
because self-report and pill count measures indicated high adherence while plasma drug 
levels suggest that product non-use was common [12]. Self-reported study product 
adherence nonetheless showed significant moderate to high correlations with pill count 
adherence in the iPrEx and Partners PrEP trials [13, 14], and self-report adherence also 
significantly predicted drug concentrations in iPrEx [13]. Understanding the patterns, 
interrelationships, and validity of various measures of study product adherence in PrEP trials 
represents an important issue; proper adherence documentation is needed to provide 
evidence for the safety and efficacy of any HIV biomedical intervention and to appropriately 
interpret the outcomes of prevention trials [15].
Limited research has examined determinants of study product adherence in oral PrEP 
clinical trials. Determinants reported to date have been largely limited to demographic and 
individual-level behavioral factors [10, 11]. Factors quantitatively associated with poor 
adherence in more than one oral PrEP trial included younger age, heavy alcohol use, and 
certain sexual risk practices and partner characteristics [11, 16, 17]. Partners PrEP 
participants who reported no sex showed lower adherence [16], and iPrEx participants 
reporting recent unprotected sex with an HIV-positive partner showed higher adherence 
[17]. iPrEx additionally observed significantly higher study product adherence among 
individuals reporting low side effects [17], as well as among U.S. (vs. non-U.S.) participants 
[18]. When asked why doses were missed, oral PrEP trial participants often report reasons 
such as forgetting [18–20], travel and schedule disruptions [18–22], and insufficient 
medication supply due to missed clinic visits [10, 23]. Qualitative studies conducted within 
oral PrEP trials additionally indicate that relationship problems [24], social costs [25], and 
concerns about HIV-related stigma [19–21] can impede adherence. Adherence facilitators 
may include use of reminder devices such as cellphone alarms [18, 19, 22, 24], the 
integration of doses into daily routines [18, 21], and social support from friends and family 
[19, 21, 24].
Data from the TDF2 trial provides an opportunity to advance the emerging research 
literature regarding the validity of adherence measures in PrEP trials, as well as factors 
associated with product adherence. Information derived from the TDF2 clinical trial may 
also help inform the implementation of PrEP delivery in real-world settings. The purpose of 
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this article is to (a) describe adherence measures used in TDF2 (pill count, self-report) and 
compare them with available drug concentration data, (b) identify factors associated with 
study product adherence, and (c) identify salient barriers and facilitators to study product 
adherence from the perspective of trial participants.
Methods
Between 2007 and 2010, we conducted TDF2, a Phase III, randomized, double-blind, 
placebo-controlled PrEP efficacy trial among sexually active, heterosexual, young adults in 
Botswana [1]. Data presented here examine demographic, behavioral, and psychosocial 
factors associated with adherence for the participants enrolled in the TDF2 study. A detailed 
description of the trial methodology is provided in the trial outcomes paper [1]. Ethical 
approval for the trial was granted in Botswana by the Human Research Development 
Committee (HRDC) under the Ministry of Health Ethics, and in the U.S. by the institutional 
review board at the Centers for Disease Control and Prevention in Atlanta, Georgia. This 
trial is registered with ClinicalTrials.gov number NCT00448669.
Sample Recruitment and Eligibility Criteria
Sexually active young adult men and women were recruited and randomized 1:1 to once-a-
day TDF/FTC or to placebo. Persons were eligible to take part in the trial if they were: 18–
39 years of age, citizens of Botswana, sexually active in the past 3 months, not pregnant, 
HIV uninfected, and able and willing to provide written informed consent.
Study Procedures
Baseline demographic and behavioral data were collected by a face-to-face interview and 
audio computer-assisted self-interview (ACASI) in the participant’s preferred language 
(English or Setswana). Monthly visits were scheduled in 30-day intervals to dispense study 
product, conduct adherence and behavioral assessment, HIV testing, and clinical evaluation. 
In addition to the monthly visit procedures, quarterly visits included risk-reduction 
counseling, blood samples for clinical safety monitoring (chemistry), and blood specimen 
storage for consenting participants. At semi-annual visits, ACASI was used to collect 
behavioral and psychosocial measures. Participants were advised to return to the clinic in the 
event of an illness or due to study pill-related concerns.
The same procedures and content for medication adherence counseling were used at the two 
sites and monitoring was conducted by an external group to ensure compliance. All 
participants received medication adherence counseling based on current interventions used 
in Botswana [26]. The adherence counseling, which included basic education about study 
medications (dose and dosing schedule, how TDF/FTC might work, recognizing and 
handling side effects, refills and drug storage), was conducted at the end of each study visit. 
In addition, adherence counseling also focused on discussing beliefs about and attitudes 
toward taking the study product, and on social and medication-related concerns and 
expectations, including pill-sharing requests from friends and family. At each monthly 
follow-up visit, study counselors reviewed the study participant’s self-reported medication 
adherence. Persons with 100 % adherence were congratulated and encouraged to continue 
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adhering to the study product. Persons reporting less than 100 % adherence, were asked to 
talk about barriers they experienced in adhering to the daily dose of the study medication, to 
identify strategies that they could use to overcoming medication-adherence barriers, and to 
create a plan for optimizing adherence.
Adherence Measures
Two primary measures were used to characterize trial participant adherence to the study 
product: self-report and pill count. The self-report measure was collected at each monthly 
visit through a face-to-face interview based on the Adult AIDS Clinical Trials Group 
Adherence Questionnaire [27]. Participants were asked to recall if they had missed a dose of 
the study product during the past three days and to report the reason for the missed dose(s). 
To assist with recall, they were asked to consult a self-kept paper-and-pencil diary record 
regarding doses taken and missed. No electronic device was used to monitor diary or 
medication use.
The pill count adherence measure was determined by counting the number of pills returned 
at every monthly visit. Participants received a 30-day supply of study medication at 
enrollment, and were asked to take one pill every day and to return all unused pills to the 
study clinic at their next monthly visit. Pills were counted and re-dispensed with a new 30-
day supply.
Drug Level Data
Plasma drug concentrations analyses were conducted using participants randomly selected 
as part of a case–control sub-study to assess the drug level among HIV seroconverters and 
non-seroconverters [1]. Twenty-three participants seroconverted while taking part in the 
TDF2 trial. Nineteen out of the 23 had been assigned to the placebo study arm and four were 
assigned to TDF/FTC. For each of these 23 seroconverters, we randomly chose three 
samples from the non-seroconverters who were assigned to the TDF/FTC arm who were 
matched on time in study, sex, and study site. Drug level samples for seroconverters were 
collected before or near the estimated date of infection, and drug level samples for the 
matched non-seroconverters were selected around the same study visit. The analysis 
presented here involves the four seroconverters assigned to TDF/FTC and 69 TDF/FTC 
matched controls, which yielded drug level measurement data for 73 participants in the 
TDF/FTC treatment arm. Given that emphasis was on assessing the correspondence between 
drug levels and adherence measures rather than on efficacy, we used all cases and control 
participants in the TDF/FTC group. Drug concentrations for tenofovir and emtricitabine 
were measured using the plasma levels of TDF/FTC in the blood via an ultra-performance 
liquid chromatograph mass spectrometry assay (lower limit of detection, 0.3 ng per milliliter 
for both TFV and FTC).
Additional Measures
Demographic information (gender, age, educational status, marital status, employment, and 
city of residence) was collected at baseline. Sexual behaviors in the past 30 days (sex with a 
main partner, sex with casual partner, and sex with anyone who has HIV) were assessed at 
baseline and at monthly follow-up visits. HIV and pregnancy (women only) tests were 
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performed at each monthly visit. Perceived study arm assignment (TDF/FTC or placebo) 
was assessed at baseline and semi-annual visits. At monthly visits, participants were also 
asked to identify strategies that facilitated or barriers that prevented daily pill-taking.
Documentation of adverse events was based on both clinical observation and self-report, and 
occurred throughout the study. Documentation of one or more of the three most significant 
adverse events (nausea, vomiting or dizziness) in TDF2 [1] was used to define the adverse 
events variable used in this analysis.
Psychosocial data were collected via ACASI on attitudes toward the study as well as on 
pregnancy intentions every 6 months. Information on alcohol and recreational drug use were 
also collected via ACASI every 6 months. During the study exit interview, participants were 
asked via CAPI about their concerns with taking the study pill and side effects was listed as 
one of the response options.
Data Analysis
The demographic, behavioral, psychosocial, and biomedical variables were summarized as 
percentages, and measures of adherence were summarized by mean and standard deviation 
by treatment assignment. We compared the correlations between pill count and self-reported 
adherence measures and also tested for time trends in both measures.
To identify factors associated with daily study product adherence, we conducted unadjusted 
and adjusted generalized estimated equations analyses. Separate models were constructed 
with monthly pill count and 3-day self-report adherence measures as the outcome variables. 
The unadjusted models used demographic, behavioral and psychosocial variables as 
covariates. The adjusted analyses included the following demographic variables: age, 
gender, education, marital status and city of residence as common factors. Additionally, 
psychosocial or behavioral factors with p value <0.1 in the unadjusted models were also 
included. Relative risks (RR), risk differences (RD) and 95 % confidence intervals (CI) were 
calculated for all models.
The relationship between TFV/FTC detection and the adherence measures (pill count and 
self-report) was explored through correlation coefficients and linear models. In the 
correlation analysis, the TFV and FTC drug-level data were dichotomized using the limit of 
detection (LOD). The pill-count data and self-report data were dichotomized at a cut point of 
0.90 to indicate high/low adherence.
We explored linear models using a log10 transformation for TFV and FTC drug levels as the 
outcome in separate models and the pill count and self-report adherence measures as 
predictor variables in addition to the demographic, behavioral and psychosocial variables 
(described previously). Our linear model treated LOD values as censored and values greater 
than or equal to LOD as the observed value. All model estimated values were back-
transformed to the original scale for TFV and FTC and interpreted as an estimate of the 
geometric mean (GM). All statistical analyses were performed using SAS software version 
9.3 (SAS Institute, Cary, NC, USA).
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Trial participant responses to open-ended questions regarding (1) reasons for missed doses 
of study product and (2) strategies used to assist with study product adherence were 
exported from the SAS database and analyzed in Microsoft Excel using an inductive content 
analysis approach. Because responses were generally brief (ranged from a single word to a 
short sentence), it was determined that Excel rather than qualitative data analysis software 
program would be sufficient for performing the analysis and would permit re-merging of 
codes with the larger SAS trial dataset. The inductive analysis process involved three careful 
readings of the English translations of all responses for the two open-ended questions, 
sorting and categorizing responses to develop and refine an analysis codebook containing 
code names and brief code definitions, and applying codes to all responses by one analyst, 
which was then followed by review of the coding by a second analyst to ensure correct 
coding of all responses. Codes (24 unique barriers and 5 unique adherence strategies) were 
enumerated to identify the most common types of responses provided to the two questions. 
In addition, trends in types of responses provided by study visit were assessed.
Results
Study Sample
Out of 2,533 persons screened, 1,345 met all study eligibility criteria. One hundred twenty-
six persons eligible to take part in the study declined enrollment. Of the 1,219 enrolled, 611 
were randomized to the TDF/FTC group and 608 were assigned to the placebo group. The 
demographic characteristics of study participants by trial arm are shown in Table 1. Median 
participant age was 25 years. Most participants in the 21–29 age group had completed 
secondary education, were single, and were unemployed. No statistically significant 
differences were observed in terms of gender, age, education, marital status, employment 
status, or city of residence by trial arm.
At baseline, approximately two-thirds of participants in each of the study arms reported a 
single sexual partner during a past 30-day period; 94 % of participants reported ever having 
a main partner and 56 % reported ever having a casual partner. When asked at baseline, 
more than 50 % reported alcohol use in a past three-month period. After six months, 11 % 
reported recreational drug use since the beginning of the study. Over the 36-month study 
period, approximately 10 % of participants self-reported having an HIV-positive sexual 
partner. See Table 1 for further details on the study participants.
Pill Count and 3-day Self-Report
Over the 36-month study period, the pill count measure showed a mean of 94.06 (95 % CI 
93.85–94.32) and a median of 100 %. The self-report measure showed a mean of 94.26 (95 
% CI 93.87–94.64) and a median of 100 %. No significant differences were observed 
between the pill count measure and the self-report measure. For the pill count, monthly 
values of adherence did not significantly decline over time (p = 0.45). Mean pill count 
adherence was 93.85 % during the first six months of study participation and 94.19 % during 
the last six months of study participation. The minimum mean value of monthly pill count 
adherence (89 %) was observed in the last month of the trial period. Monthly values of 
adherence declined over time for the self-report measure (p = 0.01). Mean self-report 
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adherence was 94.64 during the first six months of study participation and 92.97 during the 
last six months of study participation. The minimum mean value of monthly self-report 
adherence (78 %) was observed towards the end of the study in month 35. The correlation 
between pill count and self-report adherence was found to be weak but statistically 
significant (r = 0.053, p < 0.0001).
Predictors of Pill Count and 3-day Self-Report
We found few statistically significant bivariate associations between participant 
demographic characteristics and the pill count or 3-day self-report adherence measures (see 
Table 2). City of residence was associated with both the pill count and self-report, with 
higher adherence observed among participants from Francistown. Being married was 
significantly associated with greater self-reported adherence.
Greater pill count-based adherence was observed in participants who were sexually active 
with a casual partner, sexually active with a main partner, and/or reported an HIV-positive 
sexual partner in the past 30 days, had no concerns about study drug side effects, and did not 
use alcohol or drugs. Greater self-report adherence was observed in participants who were 
sexually active with a main partner, had an HIV positive sexual partner, and did not use 
alcohol or drugs. Women having no intention of being pregnant had greater adherence for 
both pill-count and self-reported adherence measures.
In a multivariable model (see Table 3), greater pill count adherence was significantly 
associated with a lack of concern about side effects and not experiencing any of the three 
common adverse events. Greater self-reported adherence was significantly associated with 
having resided in Francistown and having an HIV-positive sexual partner.
Drug Level Data
For the drug concentration analysis conducted with four seroconverters and 69 matched 
controls in the active drug arm of the trial, the phi-coefficient for the association between 
pill count adherence and detectable drug was 0.20 and 0.16, respectively, for TFV and FTC. 
The phi coefficient for self-report adherence and detectable drug was 0.28 for both TFV and 
FTC.
Results for the linear regression model of TFV and TDF are presented in supplemental file 
S1. The overall GM and 95 % CI for TFV was 24.3 ng per milliliter (ng/mL) (12.6, 46.8), 
and for FTC it was 72.1 ng/mL (29.7, 175.0). Linear regression models predicting drug level 
revealed that self-report adherence and site were statistically significant. The GM for TFV 
and FTC in Francistown [53.8 ng/mL (23.4, 124.0) and 213.5 ng/mL (71.7, 635.7)] were 
higher than in Gaborone [9.8 ng/mL (3.9, 24.9) and 24.2 ng/mL (7.2, 81.3)]. The GM ratio 
(GMr) for Francistown versus Gaborone are 5.50 (p = 0.008) for TFV and 8.82 (p = 0.009) 
for FTC. The self-report data were dichotomized using the self-report cut-point of <1.0 and 
1.0. This cut-point was chosen because 64 of the 69 participants with available self-report 
data had a value of 1.0 and the five other participants had either 0 or 1/3 recorded for self-
report. Those who self-reported <100 % adherence showed a GM of 2.0 ng/mL (0.17, 23.0) 
for TFV and 2.5 ng/mL (0.09, 67.1) for FTC, whereas those who self-reported 100 % 
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adherence showed a GM of 36.2 ng/mL (19.4, 67.5) for TDF and 122.5 ng/mL (53.0, 283.1) 
for FTC. The GMr for self-report <100 versus 100 % are 18.1 (p = 0.025; TFV) and 48.6 (p 
= 0.025; FTC). Although the GMr for pill count <90 versus ≥90 % for TFV and FTC were 
not statistically significant (p = 0.11 and 0.088, respectively), due to our limited sample size, 
the GMr were substantial (3.74 and 6.60, respectively).
Adherence Barriers and Facilitators
From the open-ended question on reasons for missed doses, the most common explanation 
for non-adherence was running out of study product (n = 643; 48 % of the reasons). Other 
common reasons given were: losing pills (n = 160; 12 %), missing doses due to travel (n = 
156 times; 12 %), forgetting to take the pill (n = 107; 8 %), and having a disruption in one’s 
daily schedule (n = 77; 6 %). Less frequently mentioned was concern about side effects (n = 
42 times; 3 %). Other less frequent reasons provided for non-adherence included disinterest 
in continuing with study participation or pill-taking, concerns about stigma, and confusion 
about the dosage schedule (1 %, collectively). In examining reasons for missed dosages over 
time, we found that this response pattern remained consistent (data not shown here).
In identifying strategies they used to improve adherence to study product in the past 30 days, 
the majority of trial participants (56 %) indicated that they had used a cell-phone alarm 
feature to remind them to take their pills. Other adherence strategies, such as relying on 
friends or integrating medication doses with daily tasks, were reported by few trial 
participants (1 %). Many trial participants (34 %) reported having no particular strategy to 
facilitate adherence.
Discussion
This study found high adherence to study product in the TDF2 trial as measured by pill 
count and self-reported adherence. Although self-report and pill count adherence may 
overestimate product adherence relative to drug concentrations, this study established that 
self-report adherence significantly predicted drug level in bivariate and controlled 
multivariate analyses. These findings establish some modest credence for the validity of the 
self-report measure. This study further identified factors predictive of self-report and pill 
count product adherence in the TDF2 PrEP trial, which constituted adverse events, concerns 
about side effects, having an HIV-positive partner, and site-level differences. Trial 
participants reported that travel and logistic barriers interfered with efforts to maintain 
adherence and study product reserves. Participants described electronic alarms as an 
important adherence facilitator, although approximately one-third of the trial sample 
reported using no strategy to facilitate adherence. These study findings and their 
implications for future PrEP trials and research are further discussed below.
The drug concentration analysis revealed a modest correlation between TDF/FTC drug level 
and self-report adherence (0.28) and a weaker relationship between drug levels and pill 
count adherence (0.20 and 0.16). Multivariate regression showed that drug level for TFV 
and FTC was associated with self-report adherence and site. Our small sample suggests that 
those who self-reported 100 % adherence had a higher amount of both TFV and FTC drugs 
in their system than those who self-reported less than 100 % adherence. There was also a 
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substantially higher amount of detectable TFV and FTC drug levels among those with pill 
counts ≥ 90 % versus those with pill counts <90 %, although this finding did not reach 
statistical significance in this small sample. These findings associating adherence pill count 
and self-report measures with drug levels diverge from results of the VOICE trial (12) and 
more closely match results from the iPrEX trial (13), which similarly reported that self-
report and pill count evidenced modest but significant associations with drug level. All of 
these trials have nonetheless found adherence by self-report and other adherence measures 
to be higher than that indicated by drug detection [11]. It is widely acknowledged that self-
report measures tend to overestimate adherence due to social desirability and recall biases 
[29, 30]. Pill count measures are also subject to various threats to validity, such as when 
social desirability concerns lead to “pill dumping” prior to scheduled study appointments 
[31]. Plasma drug concentrations present limitations as a proxy for adherence, as well; these 
include potential variation in drug pharmacokinetics, sample collection, and laboratory 
assays. Despite the limitations associated with each of these methods, the results reported 
here are reminders that these measures retain some correspondence, and further research to 
improve the collection and accuracy of inexpensive behavioral self-report measures are 
needed to aid future prevention trials and research.
This study did not find strong evidence for declines in adherence over the trial. Although 
self-report adherence significantly decreased, it was only approximately one percentage 
point lower in the final six months of study participation compared to the first six months. A 
similar pattern was observed in the Partners PrEP trial, which found modestly higher 
adherence during the first six months of study participation than the last six months [16]. 
The iPrEx trial reported that study product use decreased during the first year of use from 99 
to 91 % on the basis of drug dispensation (time-to-refill) data, whereas self-reports and pill 
count measures showed increased adherence over the same interval [3]. iPrEx also observed 
that self-reported adherence showed a significant but transient decline in the active arm at 4 
weeks, which may have been attributable to side effects associated with PrEP initiation [3].
The self-report and pill count adherence measures were very weakly correlated with one 
another, despite both showing high levels. This finding suggests that the measures could be 
assessing somewhat different constructs. Differences in the operationalization of these 
measures may account for their poor correspondence. The pill count measure assessed 
adherence based on returned pills not used over 30 days, whereas the self-report measure 
assessed adherence based on recall prompted by participants’ diary records over the prior 
three days. It may be that the longer assessment interval associated with the pill count 
measure helps to capture highly infrequent or episodic non-adherence (e.g., during 
weekends), relative to the shorter interval for the three-day self-report measure [28]. Trial 
participants did report missed doses due to travel and schedule disruptions in the adherence 
barrier data. This may have prompted intermittent gaps in adherence that might be better 
evidenced in the pill-count data than in the self-report data. A proper comparison would 
have utilized the same time frames for each measure.
Our findings show several factors associated with study product adherence in the trial. 
Demographic factors, such as age, were generally not associated with adherence by either 
pill count or self-report measure. Some PrEP trials have suggested age-related adherence 
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differences [11], but the uniformity of participant ages in the TDF2 trial may have precluded 
detection of differences in this regard. We found a relationship between site of residence and 
both pill count and self-report adherence that persisted in the multivariable model predicting 
pill count adherence. The drug level analysis additionally showed that mean drug levels 
varied by site. Site effects have been evident in prior trials, such as iPrEX, where U.S. 
participants showed higher adherence than non-U.S. participants [17]. Ready explanations 
for the site effects observed in this study are lacking. Clinics at both sites were centrally 
located and maintained the same hours of operation. An independent group monitored 
counseling to ensure consistency across the two sites. Available qualitative data (not 
reported here) also indicated no site differences in participant experiences around study 
visits, including duration, clinic wait times, or staff attitudes. It is possible that unmeasured 
ecologic factors may have played a role in the site differences.
Some behavioral and psychosocial factors were found to be associated with adherence. 
Similar to other oral PrEP trials, we found some relationships between partner 
characteristics, sexual practices, and adherence [16, 17]. Greater self-report and pill count 
adherence was observed in participants who were sexually active with a main partner, and 
who were aware that their main partner was HIV positive. These findings may indicate that 
individuals with greater perceived HIV transmission risk adhere more closely to study 
products in PrEP trials [10]; however, the magnitude of the observed differences for 
variables with statistical significance were generally small and not likely to be of strong 
clinical relevance. The Partners PrEP trial qualitative findings offer related insights in that 
serodiscordant couples’ concerns about HIV transmission risk promoted adherence to study 
product, although relationship discord could undermine this effect [24]. Lastly, while our 
multivariable model did not show that alcohol use was related to non-adherence, we did find 
univariable effects. Studies of antiretrovirals found that an the association between alcohol 
use and poor adherence was explained by strategies participants used to avoid side effects 
that come with mixing HIV medications and alcohol [32, 33].
Both concerns about and actual experiences with side effects have been shown to be barriers 
to HIV prevention and treatment adherence [34, 35]. Participants self-reporting concerns 
about side effects (e.g., nausea and diarrhea) commonly associated with TDF/FTC showed 
lower pill count adherence in the multivariable model. These findings suggest that future 
PrEP trials and PrEP implementation efforts should recognize that concerns about and actual 
experiences of side effects may have a deleterious effect on adherence, and can therefore 
compromise the efficacy of PrEP for HIV prevention. Strategies to help individuals address 
PrEP adherence while experiencing side effects should be developed.
Trial participants commonly attributed missed doses to factors such as running out of pills, 
losing pills, or losing access to pills due to travel. Citizens of Botswana travel frequently, 
especially during weekends and holidays. These data suggest that any future programs to 
address PrEP adherence should develop messages and counseling that focus on pill 
management, such as the importance of ensuring timely refills of medication and strategies 
for staying adherent when traveling away from home. Our findings showed that trial 
participants rarely mentioned side effects as a reason for missed doses, in comparison to 
some of these other, more commonly cited concerns. Thus, it may be that participants 
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perceived or attributed the greatest adherence barriers to be schedules and difficulty 
remembering, rather than to avoiding medication doses due to perceived side-effects.
The most frequently reported strategy to help with taking daily study medication was the use 
of personal cell phone reminder alarms. To improve medication adherence, increased use of 
mHealth, a healthcare delivery method that relies on the use of mobile technology, is being 
implemented [36–39]. In addition to self-regulated cell phone alarms, mobile phone short 
message service, audiovisual reminders from electronic reminder devices and pager 
messages offer potentially effective tools for improving adherence; yet, long term effects 
[40] and uptake in resource-limited settings remain unclear [41]. Moreover, issues of 
intentional (deliberately missing or altering medication doses) and unintentional (forgetting) 
non-adherence that go beyond the scope of our study suggest that these technologies may be 
more effective if used exclusively for those who are unintentionally non-adherent [40, 42]. 
Although social support from friends and relatives are cited frequently in the treatment 
adherence literature [15] participants rarely reported using friends as reminders to take study 
medications. Non-reliance on one’s social support system could have been related to 
concerns that others would assume that study participants were HIV infected because they 
were receiving HIV treatment medication. Consequentially, concerns about HIV-stigma may 
have prevented participants openly carrying or taking the study pills in public or when 
friends and family were nearby as study product packages were similar to the ARV 
containers used for HIV positive treatment. Lastly, while there may be synergies of study 
product use and oral contraceptive pill use for women that might facilitate adherence, we did 
not find evidence for this in our data (analysis not shown).
This study had several limitations. The trial was not designed to test a comprehensive model 
of adherence determinants, and so a limited number of factors could be tested in relationship 
to adherence. Additionally, drug-level data were only available on a small subsample of trial 
participants, limiting our ability to compare and test the relationships between drug detection 
and adherence as assessed by pill count or self-report. The study used a self-report 
adherence measure that has been repeatedly suggested in the literature to overestimate 
adherence relative to other adherence measures due to social desirability and recall issues. A 
self-report estimate over a longer time frame (7 days or 30 days) may better capture 
infrequent or episodic non-adherence. Finally, it is important to recognize that the analyses 
conducted here are derived from a placebo-controlled trial, so participants did not know 
whether they were taking active drug or placebo. Adherence in the context of a placebo-
controlled trial is likely to be different from adherence in an open-label trial or real-world 
use of PrEP, because trial participants are unaware whether they are receiving active drug 
and whether the active drug is efficacious. Moreover, statistically significant factors such as 
site of residence and being married showed small effect sizes and may not be clinically 
meaningful [43]. Small effect size may be attributed to the relatively large sample along 
with the lack of variability in the distribution of adherence that probably produces tight 
“clumping of data”.
In conclusion, further research is needed to understand optimal adherence measures and 
adherence determinants in biomedical HIV prevention trials. The development of improved 
behavioral adherence assessments and novel adherence biomarkers could advance the 
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sensitivity and specificity of adherence measures, which is critical to the interpretation of 
trial results. To improve adherence, support strategies in PrEP trials and real-world 
implementation should seek to address potential adherence barriers such as alcohol use, 
adverse events, side effect concerns, and logistic barriers to medication possession. Efforts 
to promote use of cellphone reminders may also provide a valuable tool for supporting 
adherence. These efforts may strengthen the ability of trials and demonstration projects to 
improve adherence to oral PrEP thereby strengthening the impact of this important new HIV 
prevention modality.
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Table 1
Characteristics of participants, BotswanaTDF2 PrEP trial, 2007–2010
Characteristics TDF/FTC n = 611 Placebo n = 608 p
Gender, n (%) Male 331 (54.2) 331 (54.4) 0.93
Female 280 (45.8) 277 (45.6)
Age group (years), n (%) 18–20 10 (1.6) 15 (2.5) 0.34
21–29 550 (90.0) 532 (87.5)
30–39 51 (8.3) 61 (10.0)
Education, n (%) Primary or less 20 (3.3) 20 (3.3) 0.996
Secondary 446 (73.0) 445 (73.2)
Postsecondary 145 (23.7) 143 (23.5)
Marital status, n (%) Married 32 (5.2) 38 (6.3) 0.45
Single 578 (94.6) 567 (93.3)
Employment status, n (%) Employed 245 (40.1) 235 (38.7) 0.61
Unemployed 366 (59.9) 373 (61.3)
City of residence, n (%) Gaborone 326 (53.4) 325 (53.5) 0.97
Francistown 285 (46.6) 283 (46.5)
Perceived TDF/FTC randomization, n (%) Yes 121 (20.1) 109 (18.4) 0.44
No 480 (79.9) 484 (81.6)
Casual partnera, n (%) Yes 339 (55.5) 345 (56.7) 0.66
No 272 (44.5) 263 (43.3)
Main partnera, n (%) Yes 580 (94.9) 562 (92.4) 0.07
No 31 (5.1) 46 (7.6)
HIV-positive partnera, n (%) Yes 58 (9.5) 65 (10.7) 0.49
No 553 (90.5) 543 (89.3)
Pregnancy occurrencea, n (%) (women only) Yes 48 (17.1) 53 (19.1) 0.54
No 232 (82.9) 224 (80.9)
Adverse eventsa,b, n (%) (nausea, dizziness, vomiting) Yes 190 (31.1) 124 (20.4) < 0.0001
No 421 (68.9) 484 (79.6)
Total sex acts in past 30 days, n (%) 0 97 (15.9) 99 (16.3) 0.98
1–2 119 (19.5) 119 (19.6)
3+ 395 (64.7) 390 (64.1)
Number of sex partners in past 30 days, n (%) 0 73 (12.2) 78 (13.1) 0.88
1 410 (68.2) 405 (67.8)
2+ 118 (19.6) 114 (19.1)
Alcohol use in past 3 months, n (%) Yes 359 (59.7) 340 (56.8) 0.30
No 242 (40.3) 259 (43.2)
Side effect concernsc,d, n (%) Yes 72 (18.9) 54 (14.1) 0.07
No 309 (81.1) 329 (85.9)
Recreational drug usee, n (%) Yes 38 (10.5) 43 (11.6) 0.64
No 325 (89.5) 329 (88.4)
Pregnancy intentione, n (%) (women only) Yes 60 (69.8) 43 (58.9) 0.15
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Characteristics TDF/FTC n = 611 Placebo n = 608 p
No 26 (30.2) 30 (41.1)
TDF everyday protecte,f, n (%) Agree 341 (86.7) 333 (83.3) 0.14
Disagree 51 (13.0) 67 (16.7)
HIV meds too stronge, n (%) Agree 244 (62.2) 208 (52.0) 0.004
Disagree 148 (37. 8) 192 (48.0)
a
Data presented are for responses at any point during the study
bCollected monthly; Presence of nausea, dizziness, and vomiting only included here. Dizziness, nausea, and vomiting were the three most common 
responses (Have you had any problems with your health since your last visit?)
cAsked at study exit
dCollected only at study exit (Response option = side effects to What concerns/problems did you have with taking the pill?)
e
Data presented are for responses at 6 months
fCollected every 6 months (TDF/FTC does not always protect you from getting HIV even if you take it every day)
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